MedCity News

SEPTEMBER 12, 2022

As the biopharma space gets more competitive and the days of blockbuster drugs seem further in the rearview, biopharma companies are investing in digital to find new and innovative ways to differentiate themselves.

Biopharma 98

Biopharma Medical Competition Patients 98

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

MedCity News

JANUARY 28, 2024

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

Competition 126

Competition Medicine Pharma Patients 126

Impetus Digital

MARCH 15, 2024

In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. However, with rapid growth comes growing pains.

Recruitment 94

Recruitment Healthcare Provider Patients Healthcare 94

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.

Competition 86

Competition Marketing Pharma Biopharma 86

pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Response rates above 50% in PD-1 high/intermediate patients with no liver tox surprises could set up for a potential acquisition.”

Pharma 100

Pharma Biopharma FDA Competition 100

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

pharmaphorum

JANUARY 3, 2023

The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months. in the evenamide group.

Side effects 102

Side effects Biopharma Patients Competition 102

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. The second to increase in patient-oriented communication and support for physicians.

Education 59

Education Physicians Healthcare Healthcare 59

Pharmaceutical Technology

JUNE 29, 2022

Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. The quality grade is even more important in many novel therapeutic modalities because the specialty enzymes often form an integral part of the product and are closer to the patient.

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

pharmaphorum

JULY 1, 2022

billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. One of the main assets of Sanofi’s $3.7 The hold on dosing applies to subjects in the trials who have received the drug for less than 60 days.

Side effects 79

Side effects Safety Biopharma Recruitment 79

MedCity News

AUGUST 3, 2022

Alnylam Pharmaceuticals drug Onpattro, an FDA-approved treatment for nerve pain caused by hereditary transthyretin amyloidosis, now has Phase 3 data showing it can also help the much larger group of patients suffering heart problems from the rare protein disease.

FDA 105

FDA Competition Pharmaceutical Patients 105

PM360

APRIL 7, 2023

Biopharma should pay special attention to this. The human interaction deficit is on average more pronounced in patients living with serious health conditions. As we plan our patient engagement strategies for the coming years, in-person interactions must be central to our vision. Trust Patient engagement is about building trust.

Biopharma 52

Biopharma Patients Specialization Networking 52

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.

Marketing 59

Marketing Biopharma Government Pharma 59

European Pharmaceutical Review

NOVEMBER 16, 2023

On the other hand, the author explained that these challenges are anticipated to be addressed through advances in technology, industry effort on implementation of standardisation and increased competition in the market. Could centrifugal bioreactor accelerate cell-therapy manufacturing?

Marketing 77

Marketing Manufacturing Biopharma Competition 77

PM360

NOVEMBER 27, 2023

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Now, due to the highly competitive environment, the process is truncated to 12-18 months. Marketing is key to adding that layer of storytelling.

Marketing 105

Marketing Customer Relationship Management Relationship management Education 105

The Marketing Advantage

MAY 8, 2023

May 9, 2023 Since the Orphan Drug Act was passed in 1983, the number of products being researched and approved for rare and orphan diseases has increased dramatically, offering hope and life-saving treatments for the millions of patients affected by these often under-served conditions.

Sales 52

Sales Physicians Consulting Education 52

European Pharmaceutical Review

DECEMBER 19, 2022

Nonetheless, some stakeholders remain concerned with this new approach given the complexity of biological medicines and the need for patients to be treated individually and have called for further discussions with regulators and all stakeholders. What are the concerns about the interchangeability of biosimilars?

Medicine 52

Medicine Biopharma Safety Food 52

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Clarivate

OCTOBER 25, 2023

The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs. Impact for patients taking the diabetes drugs and blood thinners might be less noticeable since these drugs tend to receive coverage as preferred brand tiers with copays.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

SEPTEMBER 26, 2023

One of the critical factors determining the success of a clinical trial is the selection of appropriate clinical sites that have evidenced access to specific patient populations. Patient recruitment accounts for 32% of all trial costs and patient drop out averages 18%, according to Deloitte figures. Food and Drug Administration.

Food and Drug Administration 59

Food and Drug Administration Electronics Patients Healthcare 59

MedCity News

JUNE 16, 2023

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 119

Pharma Food and Drug Administration Recruitment Pharmacology 119

Zymewire

FEBRUARY 8, 2024

Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? What unmet needs are you hoping to address for patients?

Competition 52

Competition Leads Patients Marketing 52

Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52

Retail Healthcare Healthcare Physicians 52

pharmaphorum

JANUARY 27, 2023

An additional note of optimism is that UK biotechs achieved pivotal milestones in their development, with Verona Pharma reporting a successful phase 3 trial for Ensifentrine, the first novel compound in over 10 years to address the ongoing needs of more than 380 million patients worldwide suffering from Chronic Obstructive Pulmonary Disease (COPD).

Pharma 52

Pharma Manufacturing Biopharma Medicine 52

Pharmaceutical Technology

NOVEMBER 23, 2022

One of the primary focus areas includes the continued commercialisation of cutting-edge cell and gene therapies, which involve the modification of cells from patients or donors to produce highly personalised therapies and regenerative medicines. City Competitiveness Index. per square foot (/ft2) in Hamilton, versus C$9.06/ft2

Marketing 52

Marketing Manufacturing Transportation Government 52

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. These health systems combine multiple sites and services, and sometimes a health maintenance organization, to provide end-to-end care to patients locally or regionally. states and the United Kingdom and sees more than 35 million patient encounters per year. ChristianaCare, Wilmington, Delaware.

Networking 52

Networking Healthcare Healthcare Competition 52

Pharmaceutical Technology

JUNE 15, 2023

Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. Clinical trial monitoring Completing clinical studies more quickly can mean critical medicines and treatments reach patients faster. How is AI used in the pharmaceutical industry?

Pharma 52

Pharma Management Networking Manufacturing 52

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Positive outcomes in a key patient segment could broaden TRODELVY’s uptake in metastatic breast cancer. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

Pharmaceutical Technology

DECEMBER 20, 2022

Companies are recognizing the importance of working together to advance science, improve solutions, and best serve patients. Maintaining sterility is critical in the final steps of parenteral drug processing, ensuring doses are free from microbial contamination that could affect patient safety. You certainly wouldn’t share data.

Biopharma 52

Biopharma Manufacturing FDA Pharmaceutical 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. In January 2023, VillageMD acquired Summit Health for $8.9

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

OCTOBER 19, 2023

The most important benefit is that it can deliver efficacious therapeutics to patients awaiting treatment much faster. Another non-negligible benefit is that it can increase the return on investment for pharmaceutical companies trying to put a new medicine on the market, as compared to traditional drug discovery approaches.

Networking 59

Networking Consulting Safety Side effects 59

Clarivate

MAY 24, 2023

Food and Drug Administration advisory committee’s narrow 8-6 vote in favor of recommending accelerated approval for a first-in-class gene transfer therapy was welcomed by Duchenne muscular dystrophy (DMD) patients and caregivers. Most patients must use a wheelchair by the time they are in their teens.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

Clarivate

OCTOBER 7, 2021

Clarivate oncology experts share major takeaways from ESMO and their expected impact on the treatment landscape and patients. Introduced earlier in the treatment paradigm, Keytruda could substantially reduce risk of recurrence in high-risk early-stage melanoma patients. Context: In August 2021, Merck & Co. in the placebo group.

Patients 91

Patients Safety Marketing Physicians 91